CVRx, Inc. (CVRX), a cardiovascular medical device company, has initiated BENEFIT-HF, a clinical trial to evaluate the impact of Barostim, an FDA-approved implantable device, in an expanded heart failure population.
Barostim is an implantable device that delivers electrical signals to baroreceptors located on the carotid artery, increasing baroreflex signalling, rebalancing the autonomic nervous system, and improving heart failure symptoms.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com